S S Dalvi

785 total citations
29 papers, 554 citations indexed

About

S S Dalvi is a scholar working on Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health and Pharmacology. According to data from OpenAlex, S S Dalvi has authored 29 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pediatrics, Perinatology and Child Health, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Pharmacology. Recurrent topics in S S Dalvi's work include Malaria Research and Control (8 papers), Mosquito-borne diseases and control (6 papers) and Pharmaceutical studies and practices (6 papers). S S Dalvi is often cited by papers focused on Malaria Research and Control (8 papers), Mosquito-borne diseases and control (6 papers) and Pharmaceutical studies and practices (6 papers). S S Dalvi collaborates with scholars based in India, Canada and France. S S Dalvi's co-authors include Nilima Kshirsagar, Nithya Gogtay, N A Kshirsagar, Prafulla C. Gokhale, Dimple Rajgor, Jehangir S Sorabjee, Kevin C. Kain, M. R. Garg, Insa Gathmann and Saaketh Desai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Ethnopharmacology and European Journal of Pharmacology.

In The Last Decade

S S Dalvi

25 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S S Dalvi India 12 202 141 119 104 86 29 554
Teresa Bailey Klepser United States 9 183 0.9× 35 0.2× 73 0.6× 118 1.1× 31 0.4× 12 523
Anna Drew Australia 11 154 0.8× 133 0.9× 73 0.6× 93 0.9× 49 0.6× 13 517
Laura Shane‐McWhorter United States 17 137 0.7× 86 0.6× 56 0.5× 76 0.7× 55 0.6× 35 722
Bhawana Sharma India 15 84 0.4× 128 0.9× 45 0.4× 82 0.8× 112 1.3× 38 918
Wing‐Tat Poon Hong Kong 15 62 0.3× 129 0.9× 135 1.1× 33 0.3× 44 0.5× 30 494
Carmela Santuccio Italy 11 123 0.6× 39 0.3× 124 1.0× 34 0.3× 57 0.7× 21 706
Robert P. Mozersky United States 6 154 0.8× 98 0.7× 98 0.8× 47 0.5× 25 0.3× 13 468
Cathi Dennehy United States 16 207 1.0× 131 0.9× 199 1.7× 104 1.0× 97 1.1× 33 941
Seyedeh Parisa Moosavian Iran 19 57 0.3× 229 1.6× 88 0.7× 95 0.9× 39 0.5× 44 959
Eshetie Melese Birru Ethiopia 18 110 0.5× 88 0.6× 113 0.9× 239 2.3× 103 1.2× 36 677

Countries citing papers authored by S S Dalvi

Since Specialization
Citations

This map shows the geographic impact of S S Dalvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S S Dalvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S S Dalvi more than expected).

Fields of papers citing papers by S S Dalvi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S S Dalvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S S Dalvi. The network helps show where S S Dalvi may publish in the future.

Co-authorship network of co-authors of S S Dalvi

This figure shows the co-authorship network connecting the top 25 collaborators of S S Dalvi. A scholar is included among the top collaborators of S S Dalvi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S S Dalvi. S S Dalvi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dalvi, S S, et al.. (2004). Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology. 98(5). 525–528. 13 indexed citations
2.
3.
Dalvi, S S, et al.. (2004). Safety monitoring: An Indian perspective. International Journal of Risk & Safety in Medicine. 16(1). 21–30. 2 indexed citations
4.
Gogtay, Nithya, et al.. (2004). Safety issues in Indian traditional medicine. International Journal of Risk & Safety in Medicine. 16(2). 73–82. 2 indexed citations
5.
Gogtay, Nithya, et al.. (2003). A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai, India.. PubMed. 51. 877–9. 6 indexed citations
7.
Rajgor, Dimple, et al.. (2003). Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 97(4). 438–440. 26 indexed citations
8.
Gogtay, Nithya, et al.. (2002). The Use and Safety of Non-Allopathic Indian Medicines. Drug Safety. 25(14). 1005–1019. 205 indexed citations
9.
Dalvi, S S, et al.. (2001). A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic‐clonic epilepsy. British Journal of Clinical Pharmacology. 52(2). 193–195. 19 indexed citations
10.
Kshirsagar, N A, M. R. Garg, S S Dalvi, et al.. (2000). A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India.. American Journal of Tropical Medicine and Hygiene. 62(3). 402–408. 35 indexed citations
11.
Kshirsagar, Nilima, et al.. (2000). An unusual case of multidrug-resistant Plasmodium vivax malaria in Mumbai (Bombay), India. Annals of Tropical Medicine and Parasitology. 94(2). 189–190. 9 indexed citations
12.
Gogtay, Nithya, et al.. (1999). Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses inPlasmodium vivaxinfections. Annals of Tropical Medicine and Parasitology. 93(8). 809–812. 19 indexed citations
13.
Kshirsagar, N A, Nithya Gogtay, & S S Dalvi. (1999). THERAPEUTIC DRUG MONITORING (TDM) SERVICES IN DEVELOPING COUNTRY.. Therapeutic Drug Monitoring. 21(4). 429–429.
14.
Karande, Sunil, S S Dalvi, & N A Kshirsagar. (1995). Shortcomings in the Pharmacotherapy of Epileptic Children in Bombay, India. Journal of Tropical Pediatrics. 41(4). 247–249. 7 indexed citations
15.
Dalvi, S S, et al.. (1994). Effect of gugulipid on bioavailability of diltiazem and propranolol.. PubMed. 42(6). 454–5. 29 indexed citations
16.
Dalvi, S S, et al.. (1993). Compliance monitoring in epileptic patients.. PubMed. 41(7). 431–2. 11 indexed citations
17.
Dalvi, S S, et al.. (1992). Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation. Journal of Ethnopharmacology. 35(3). 285–288. 50 indexed citations
18.
Gokhale, Prafulla C., et al.. (1990). Bioinequivalence of marketed diltiazem preparations. European Journal of Clinical Pharmacology. 39(2). 189–190. 4 indexed citations
19.
Pathare, Anil, et al.. (1988). Association of tuberculoma with arterio-venous malformation (a case report).. SHILAP Revista de lepidopterología. 1 indexed citations
20.
Dalvi, S S, et al.. (1985). Bioavailability of aspirin after oral and rectal administration in volunteers and patients with fever.. SHILAP Revista de lepidopterología. 31(4). 192–5. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026